Contents
Issue 125 • December 2022
In association with
In association with
Comment
GSK speeds up the race to market first RSV vaccine for older adults
Biden’s directive on foreign biotech investments impacts manufacturers
Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data
‘Twindemic’ risks warrant immediate steps in Europe and the US
A game of two halves for Roche’s recently approved wet AMD assets
In Depth
What Rishi Sunak can do for the UK pharma industry
Inside the European mass shift to data-driven health solutions
Chronic drug shortages signal difficult outlook for cardiovascular care
Can gene therapies for haemophilia defend their high price tags?
Trial termination analysis unveils a silver lining for patient recruitment
New dawn for the EU's joint procurement crisis response
Comment
GSK speeds up the race to market first RSV vaccine for older adults